Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
The prognostic significance of the histopathological variants of Focal Segmental Glomerulosclerosis (FSGS), particularly the rare Cellular (CELL) and Peri-hilar (PH) subtypes, remains a subject of debate. This study aimed to define the relative frequency, clinico-pathological features, and outcomes of these variants in a single-center cohort.
A retrospective analysis was conducted on 401 adult patients with biopsy-proven primary FSGS diagnosed between 1995 and 2017. Histological classification followed the Columbia criteria. This study focuses on the detailed analysis of the CELL (n=6) and PH (n=3) variants. All patients were treated with a standardized protocol of corticosteroids, with cyclosporine A (CsA) used for steroid-resistant or dependent cases. The primary outcomes were rates of complete remission (CR), partial remission (PR), progression to kidney failure with replacement therapy (KFRT), and mortality.
Among 352 patients with a designated FSGS variant, the CELL and PH variants were the least common, comprising 1.5% (n=6) and 0.7% (n=3) of the cohort, respectively. At presentation, both groups had comparable demographics, severe nephrotic-range proteinuria (median: CELL 3565.5 mg/24h, PH 4338 mg/24h), and preserved initial kidney function. Outcomes, however, diverged significantly. The CELL variant was associated with a dismal prognosis: 0% (0/6) achieved CR, 83.3% (5/6) had no remission, 83.3% (5/6) progressed to KFRT, and 50.0% (3/6) died. In contrast, the PH variant showed a more favorable course, with 33.3% (1/3) achieving CR, 0% progressing to KFRT, and 0% mortality.
Despite similar clinical presentations, the Cellular variant of FSGS is associated with extreme treatment resistance and a high risk of progression to kidney failure and death, whereas the Peri-hilar variant demonstrates a more favorable outcome in this cohort. These findings underscore the critical prognostic value of the Columbia classification and highlight the aggressive nature of the CELL variant, necessitating vigilant management and further study.
